Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the...
Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus ...
Infobip Shift 2025: One of Europe’s Largest Developer Conferences Takes Place...
Expanding to a third continent and connecting developers across global tech hubs KUALA LUMPUR, Malaysia, Nov. 7, 2025 /PRNewswire/ -- Infobip Shift, one of the most attended developer conferences, was held in Asia for the first time, in Kuala Lumpur, a city known for its growing tech and...
Alvotech Provides Update on the Status of U.S. Biologics License Application for...
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics...
Nova Leap Health Corp. Posts Best Financial Performance in Company History...
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce the release...
